UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers

Circulation Cardiovascular quality and outcomes, 2018-01, Vol.11 (1), p.e003939-e003939

2018

Volltextzugriff (PDF)

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

Leukemia & lymphoma, 2023-12, Vol.64 (14), p.2316-2323

2023

Volltextzugriff (PDF)

Barriers and solutions to improve access for chimeric antigen receptor therapies

Immunotherapy, 2022-06, Vol.14 (9), p.741-753

2022

Volltextzugriff (PDF)

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting

Journal of managed care & specialty pharmacy, 2024-10, Vol.30 (10), p.1106-1116

2024

Volltextzugriff (PDF)

Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries

Journal of managed care & specialty pharmacy, 2021-10, Vol.27 (10), p.1457-1468

2021

Volltextzugriff (PDF)

Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions

Value in health, 2020-02, Vol.23 (2), p.209-216

2020

Volltextzugriff (PDF)

CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S277-S278

2022

Volltextzugriff (PDF)

Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2020-02, Vol.8 (2), p.507-515.e10

2020

Volltextzugriff (PDF)

Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia

Cancer medicine (Malden, MA), 2024-01, Vol.13 (2), p.e6953-n/a

2024

Volltextzugriff (PDF)

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes

Open forum infectious diseases, 2022-10, Vol.9 (10), p.ofac435-ofac435

2022

Volltextzugriff (PDF)

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

Blood, 2023-11, Vol.142 (Supplement 1), p.2326-2326

2023

Volltextzugriff (PDF)

647: REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-157-S-157

2022

Volltextzugriff (PDF)

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

ClinicoEconomics and outcomes research, 2024-08, Vol.16, p.567-579

2024

Volltextzugriff (PDF)

Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting

Blood, 2023-11, Vol.142 (Supplement 1), p.5085-5085

2023

Volltextzugriff (PDF)

Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs . BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S180-S180

2024

Volltextzugriff (PDF)

CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S345-S346

2024

Volltextzugriff (PDF)

Poster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S143

2022

Volltextzugriff (PDF)

15. Real-World Changes in Clostridioides difficile infection (CDI) Treatment Utilization and Clinical Outcomes Associated with Updated 2017 IDSA Guidelines among Medicare Beneficiaries in the U.S

Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S11-S11

2021

Volltextzugriff (PDF)

Advocating for New Patient-Centered Tools for Value-Based Treatment Choices in Oncology

Journal of clinical pathways : the foundation of value-based care, 2019-03, Vol.5 (2), p.44-47

2019

Volltextzugriff (PDF)

Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction

Journal of the American Heart Association, 2020-03, Vol.9 (5), p.e014941-e014941

2020

Volltextzugriff (PDF)

Exploring Mediators of Food Insecurity and Obesity: A Review of Recent Literature

Journal of community health, 2012-02, Vol.37 (1), p.253-264

2012

Volltextzugriff (PDF)

Trachymyrmex septentrionalis ants promote fungus garden hygiene using Trichoderma -derived metabolite cues

Proceedings of the National Academy of Sciences - PNAS, 2023-06, Vol.120 (25), p.e2219373120-e2219373120

2023

Volltextzugriff (PDF)

Evaluation of the Dermatology Physician Assistant Workforce in the US

JAMA dermatology (Chicago, Ill.), 2022-06, Vol.158 (6), p.693

2022

Volltextzugriff (PDF)

Novel elements of value in the context of oncology

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e18823-e18823

2021

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(50)
Dissertationen
(1)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia

Barriers and solutions to improve access for chimeric antigen receptor therapies

Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline setting

Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries

Trends and Factors Associated With Insurer Approval of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Prescriptions

CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia

Omalizumab Treatment Patterns Among Patients with Asthma in the US Medicare Population

Real‐world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes

Real-World Treatment Patterns, Overall Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients with Mantle Cell Lymphoma (MCL) after Failure of Covalent Btki Treatment

647: REAL-WORLD COMPARATIVE EFFECTIVENESS OF FIDAXOMICIN VS. VANCOMYCIN AMONG MEDICARE BENEFICIARIES WITH CLOSTRIDIOIDES DIFFICILE INFECTION

Real-World Adherence and Discontinuation of Oral Antipsychotics and Associated Factors in a National Sample of US Medicare Beneficiaries with Schizophrenia

Real-World Comparison of Healthcare Costs of Venetoclax-Obinutuzumab Vs. Btki Use Among Elderly U.S. Medicare Beneficiaries with Chronic Lymphocytic Leukemia in the Front-Line (1L) Setting

Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs . BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)

CLL-171 Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA)

Poster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia

15. Real-World Changes in Clostridioides difficile infection (CDI) Treatment Utilization and Clinical Outcomes Associated with Updated 2017 IDSA Guidelines among Medicare Beneficiaries in the U.S

Advocating for New Patient-Centered Tools for Value-Based Treatment Choices in Oncology

Interleukin-1 Blockade Inhibits the Acute Inflammatory Response in Patients With ST-Segment-Elevation Myocardial Infarction

Exploring Mediators of Food Insecurity and Obesity: A Review of Recent Literature

Mass spectrometry searches using MASST

Trachymyrmex septentrionalis ants promote fungus garden hygiene using Trichoderma -derived metabolite cues

Evaluation of the Dermatology Physician Assistant Workforce in the US

Novel elements of value in the context of oncology

Suchergebnisse filtern